Trexquant Investment LP Makes New $604,000 Investment in Enfusion, Inc. (NYSE:ENFN)

Trexquant Investment LP bought a new position in shares of Enfusion, Inc. (NYSE:ENFN - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 58,681 shares of the company's stock, valued at approximately $604,000.

Several other institutional investors have also recently made changes to their positions in the business. Geode Capital Management LLC grew its position in Enfusion by 2.1% during the 4th quarter. Geode Capital Management LLC now owns 1,050,549 shares of the company's stock worth $10,823,000 after purchasing an additional 21,183 shares during the period. Wellington Management Group LLP boosted its stake in shares of Enfusion by 6.1% in the fourth quarter. Wellington Management Group LLP now owns 1,035,996 shares of the company's stock worth $10,671,000 after buying an additional 59,700 shares during the last quarter. Arrowstreet Capital Limited Partnership acquired a new stake in Enfusion during the fourth quarter worth about $2,358,000. JPMorgan Chase & Co. raised its position in Enfusion by 45.8% during the fourth quarter. JPMorgan Chase & Co. now owns 303,332 shares of the company's stock valued at $3,124,000 after acquiring an additional 95,310 shares in the last quarter. Finally, Fox Run Management L.L.C. acquired a new position in Enfusion in the fourth quarter valued at approximately $265,000. Hedge funds and other institutional investors own 81.05% of the company's stock.

Enfusion Stock Performance

Shares of NYSE:ENFN traded down $0.02 during midday trading on Thursday, reaching $10.78. 279,494 shares of the company's stock traded hands, compared to its average volume of 620,753. The company has a fifty day simple moving average of $11.09 and a two-hundred day simple moving average of $10.39. Enfusion, Inc. has a 1 year low of $7.83 and a 1 year high of $11.80. The company has a market cap of $1.39 billion, a P/E ratio of 269.69, a PEG ratio of 1.85 and a beta of 0.92.

Enfusion (NYSE:ENFN - Get Free Report) last announced its earnings results on Monday, March 3rd. The company reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.02). Enfusion had a net margin of 1.70% and a return on equity of 6.67%. The company had revenue of $52.94 million during the quarter, compared to analyst estimates of $53.98 million. As a group, research analysts forecast that Enfusion, Inc. will post 0.06 EPS for the current fiscal year.

Insider Buying and Selling

In other Enfusion news, COO Neal Pawar sold 14,560 shares of Enfusion stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $11.38, for a total transaction of $165,692.80. Following the sale, the chief operating officer now owns 1,217,067 shares of the company's stock, valued at $13,850,222.46. The trade was a 1.18 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Oleg Movchan sold 2,790 shares of the company's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $11.48, for a total transaction of $32,029.20. Following the sale, the chief executive officer now directly owns 643,299 shares of the company's stock, valued at $7,385,072.52. The trade was a 0.43 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 66,223 shares of company stock worth $754,778. Insiders own 36.44% of the company's stock.

Analysts Set New Price Targets

ENFN has been the topic of a number of analyst reports. William Blair reaffirmed a "market perform" rating on shares of Enfusion in a research note on Monday, January 13th. Piper Sandler lifted their price objective on shares of Enfusion from $10.00 to $11.50 and gave the company a "neutral" rating in a report on Monday, December 23rd. Finally, Stifel Nicolaus increased their target price on shares of Enfusion from $11.00 to $13.00 and gave the stock a "buy" rating in a research note on Wednesday, December 18th.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.